PRTK Paratek Pharmaceuticals Inc.

3.76
-0.02  -1%
Previous Close 3.78
Open 3.78
Price To Book 7.67
Market Cap 121,884,074
Shares 32,415,977
Volume 173,673
Short Ratio
Av. Daily Volume 323,618

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Intermezzo
Insomnia
Phase 3 data released July 17, 2017 - all endpoints met.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Community-acquired bacterial pneumonia (CABP)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
Phase 2 data due 2H 2019.
Omadacycline
Urinary tract infections
Phase 2 data due 2H 2019.
Omadacycline
Complicated urinary tract infections (cUTI) / acute pyelonephritis

Latest News

  1. Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
  2. Biotech companies dominate fastest-growing public companies list again
  3. Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
  4. Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
  5. Edited Transcript of PRTK earnings conference call or presentation 8-May-19 8:30pm GMT
  6. Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates
  7. Paratek: 1Q Earnings Snapshot
  8. Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market
  9. Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for
  10. Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019
  11. Should You Be Pleased About The CEO Pay At Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK)
  12. Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
  13. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  14. Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
  15. Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
  16. Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
  17. Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference
  18. Seth Klarman's Small Caps: Worth a Look?
  19. Paratek Pharmaceuticals Announces Management Change
  20. What Should Investors Know About Paratek Pharmaceuticals, Inc.’s (NASDAQ:PRTK) Future?